CORDIS
EU research results

CORDIS

English EN

Research, selection and mechanism of action of potential therapeutic agents against flaviviridae (hepatitis c virus, dengue virus, west nile virus,)

Objective

Our objective is to provide new nucleoside analogues, modified on their base or sugar moieties, interfering specifically with the replication of Flaviviridae viruses. These molecules will than be suitable for advanced preclinical and clinical development. Five of the leading European groups will join their efforts with a research and development SME pharmaceutical company. We intend to investigate the activity of newly synthesised lead compounds that inhibit the replication of various Flaviviridae viruses. Evaluation (using virology, enzymologist, toxic-pharmacology assays and 3D modelling) will provide the data for structure activity relationship analysis and will be used to direct further chemical orientation. The outcome is the production, based on rational approach, of the best molecule in terms of design, low toxicity, biological evaluation and development of-new anti-viral agents against this viral family as a whole.

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Address

Place EugÈNe Bataillon Cc008
34095 Montpellier

France

Administrative Contact

Michel RETOURNA

Participants (8)

Sort alphabetically

Expand all

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France

IDENIX PHARMACEUTICALS INC

United States

IDENIX SARL

France

UNIVERSITAET OSNABRUECK

Germany

UNIVERSITE DE LA MEDITERRANEE D'AIX-MARSEILLE II

France

UNIVERSITE DE MONTPELLIER II - SCIENCES ET TECHNIQUES DU LANGUEDOC

France

UNIVERSITY OF CAGLIARI

Italy

UNIVERSITÉ DE PROVENCE, AIX-MARSEILLE

France

Project information

Grant agreement ID: QLK3-CT-2001-00506

  • Start date

    1 January 2002

  • End date

    31 December 2004

Funded under:

FP5-LIFE QUALITY

  • Overall budget:

    € 3 350 972

  • EU contribution

    € 1 902 308

Coordinated by:

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France